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Risk factors associated with revision for prosthetic joint 
infection after hip replacement: a prospective observational 
cohort study
Erik Lenguerrand, Michael R Whitehouse, Andrew D Beswick, Setor K Kunutsor, Ben Burston, Martyn Porter, Ashley W Blom*
Summary
Background The risk of prosthetic joint infection (PJI) is influenced by patient, surgical, and health-care factors. 
Existing evidence is based on short-term follow-up. It does not differentiate between factors associated with early 
onset caused by the primary intervention from those associated with later onset more likely to result from 
haematogenous spread. We aimed to assess the overall and time-specific associations of these factors with the risk of 
revision due to PJI after primary total hip replacement.
Methods We did a prospective observational cohort study analysing 623 253 primary hip procedures performed 
between April 1, 2003, and Dec 31, 2013, in England and Wales and recorded the number of procedures revised 
because of PJI. We investigated the associations between risk factors and risk of revision for PJI across the overall 
follow-up period using Poisson multilevel models. We reinvestigated the associations by post-operative time periods 
(0–3 months, 3–6 months, 6–12 months, 12–24 months, >24 months) using piece-wise exponential multilevel models 
with period-specific effects. Data were obtained from the National Joint Registry linked to the Hospital Episode 
Statistics data.
Findings 2705 primary procedures were subsequently revised for an indication of PJI between 2003 and 2014, after a 
median (IQR) follow up of 4·6 years (2·6–7·0). Among the factors associated with an increased revision due to PJI there 
were male sex (1462 [1·2‰] of 1 237 170 male-years vs 1243 [0·7‰] of 1 849 691 female-years; rate ratio [RR] 1·7 [95% CI 
1·6–1·8]), younger age (739 [1·1‰] of 688 000 person-years <60 years vs 242 [0·6‰] of 387 049 person-years ≥80 years; 
0·7 [0·6–0·8]), elevated body-mass index (BMI; 941 [1·8‰] 517 278 person-years with a BMI ≥30 kg/m² vs 272 [0·9‰] 
of 297 686 person-years with a BMI <25 kg/m²; 1·9 [1·7–2·2]), diabetes (245 [1·4‰] 178 381 person-years with diabetes 
vs 2120 [1·0‰] of 2 209 507 person-years without diabetes; 1·4 [1·2–1·5]), dementia (5 [10·1‰] of 497 person-years with 
dementia at 3 months vs 311 [2·6‰] of 120 850 person-years without dementia; 3·8 [1·2–7·8]), previous septic arthritis 
(22 [7·2‰] of 3055 person-years with previous infection vs 2683 [0·9‰] of 3 083 806 person-years without previous 
infection; 6·7 [4·2–9·8]), fractured neck of femur (66 [1·5‰] of 43 378 person-years operated for a fractured neck of 
femur vs 2639 [0·9‰] of 3 043 483 person-years without a fractured neck of femur; 1·8 [1·4–2·3]); and use of the lateral 
surgical approach (1334 [1·0‰] of 1 399 287 person-years for lateral vs 1242 [0·8 ‰] of 1 565 913 person-years for posterior; 
1·3 [1·2–1·4]). Use of ceramic rather than metal bearings was associated with a decreased risk of revision for 
PJI (94 [0·4‰] of 239 512 person-years with ceramic-on-ceramic bearings vs 602 [0·5‰] of 1 114 239 peron-years with 
metal-on-polyethylene bearings at ≥24 months; RR 0·6 [0·4–0·7]; and 82 [0·4‰] of 190 884 person-years with ceramic-
on-polyethyene bearings vs metal-on-polyethylene bearings at ≥24 months; 0·7 [0·5–0·9]). Most of these factors had 
time-specific effects. The risk of revision for PJI was marginally or not influenced by the grade of the operating surgeon, 
the absence of a consultant surgeon during surgey, and the volume of procedures performed by hospital or surgeon. 
Interpretation Several modifiable and non-modifiable factors are associated with the risk of revision for PJI after primary 
hip replacement. Identification of modifiable factors, use of targeted interventions, and beneficial modulation of some of 
these factors could be effective in reducing the incidence of PJI. It is important for clinicians to consider non-modifiable 
factors and factors that exhibit time-specific effects on the risk of PJI to counsel patients appropriately preoperatively.
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Introduction
Hip replacement is a successful and cost-effective elec- 
tive surgical intervention that is widely used to treat 
disabling joint pain, mainly caused by osteoarthritis. 
Some patients experience complications and one of the 
most severe is prosthetic joint infection (PJI),1 which is 
most commonly caused by coagulase-negative staphylo-
coccus or Staphylococcus aureus.2 Although uncommon, 
PJI is devastating and leads to severe pain, poor function, 
reduced quality of life, and even death.1,3 The treatment 
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burden is high for patients and health-care systems.4 
Revision surgery is usually required and is complex, 
protracted, and associated with further complications.5,6 
A large rise in the number of primary hip replacements 
is predicted7 and a proportionate rise in the number of 
patients requiring revision for PJI is expected.8 In 
England and Wales alone, over 1000 revision procedures 
are performed annually because of PJI of the hip.9
Identification of individuals at high risk of PJI helps 
to inform the development of preventive strategies and 
optimise the detection of PJI. The risk of developing 
PJI is influenced by non-modifiable and modifiable 
patient, surgical, and health-care characteristics. In our 
systematic review10 of patient risk factors for PJI, we 
identified male sex, smoking, increasing body-mass 
index (BMI), steroid use, previous joint surgery, and 
comorbidities, such as diabetes, rheumatoid arthritis, 
and depression. Limitations of this review included 
short-term follow-up, pooled estimates based on 
variably adjusted data, and evidence of substantial 
heterogeneity between study settings. These limitations 
are also applicable to other systematic reviews of 
surgical and health-care system factors associated with 
revision for PJI.11,12
Given these limitations, large-scale cohort studies are 
needed with adequate power to provide evidence on the 
nature and magnitude of the associations of potential 
risk factors for PJI. It is important to disentangle factors 
associated with early onset of PJI, which are likely to be 
the consequence of the primary intervention, from 
factors associated with later onset, which are more likely 
to result from haematogenous spread.6
We aimed to assess the overall and postoperative 
period-specific associations of patient, surgical, and 
Research in context
Evidence before this study
Prosthetic joint infection (PJI) is a devastating complication after 
hip replacement. In a systematic review published in 2016, 
we searched MEDLINE, Embase, Web of Science, and The 
Cochrane Library databases from inception up to Sept 1, 2015, 
using a registered protocol (PROSPERO: CRD42015023485) to 
identify the role of patient characteristics on the risk of 
developing PJI. Our search strategy combined terms related to 
exposures (eg, “risk factor”, “body mass index”, “comorbidity”) 
with those related to outcomes (eg, “periprosthetic joint 
infection”, “prosthetic joint infection”, “deep prosthetic 
infection”, “deep infection”, “deep surgical site infection”). 
Longitudinal studies that reported on the associations of any 
patient factors with PJI after primary or revision total 
arthroplasty, who had at least 12 months of follow-up and who 
had a Newcastle-Ottawa Scale score of more than 5 were eligible. 
512 508 hip replacements were pooled and showed that male 
sex, high body-mass index (BMI), steroid use, diabetes, 
rheumatoid arthritis, congestive heart failure, depression, and 
smoking and alcohol intake are each associated with an increased 
risk of PJI. The published literature was limited by short-term 
postoperative follow-up, variably adjusted data which did not 
enhance consistent comparison, substantial heterogeneity 
between contributing studies, and by not disentangling factors 
associated with early onset of PJI caused by the primary 
intervention from factors associated with later onset resulting 
from haematogenous spread. Older reviews had investigated the 
role of surgical intervention and health-care setting factors on 
the risk of revision for PJI but were also limited by the size of the 
studied samples, infected cases, short postoperative follow-up 
(≤12 months), and between study heterogeneity.
Repeating the search on March 19, 2018, we identified 
two registry studies and a meta-analysis published since our 
previous review. Registry studies from Denmark and 
New Zealand observed increased risk of PJI in men, older 
patients, those with a high BMI, and those with rheumatoid 
arthritis. The meta-analysis showed weak evidence of reduced 
risk of PJI for non-metallic bearing surfaces. The authors 
highlighted the need for larger studies with adjustment for 
confounders.
Added value of this study
This study investigated the overall and postoperative 
period-specific effects of patient, surgical, and health system 
factors on the risk of revision for PJI, with a single dataset of 
623 053 primary hip replacements in which patients were 
followed up for up to 11 years. Considering patient 
characteristics, this work corroborates the previous findings of 
our review and identifies other factors such as younger age, 
chronic pulmonary disease, liver disease, and dementia that are 
associated with an increased risk of PJI. Surgical factors, 
including indication for the primary surgery, surgery type, the 
lateral surgical approach, and non-ceramic bearing surfaces, 
were associated with an increased risk of PJI. We identified no 
effects or only small effects for surgeon and hospital volume or 
surgeon grade. More importantly, we identified that these 
factors have a different effect according to the postoperative 
period considered, with comorbidities such as dementia 
influencing early revision for PJI and liver diseases influencing 
long-term revision. The effect of bearing surfaces also varied 
according to the period considered but factors, such as age or 
BMI, increased the risk during all postoperative periods.
Implications of all the available evidence
The risk of revision for PJI after primary hip replacement is 
multifactorial, mainly driven by patient and surgical level 
factors with time-varying effects. The modifiable factors 
identified in this study should be considered by clinicians in 
their practice to develop targeted interventions and propose 
beneficial modulation of some of these factors. Of equal 
importance is for clinicians to consider the non-modifiable 
factors and the factors that exhibit time-specific effects on the 
risk of PJI, to counsel patients appropriately preoperatively.
Articles
1006 www.thelancet.com/infection   Vol 18   September 2018
health-care setting factors with the risk of revision due 
to PJI in prospectively collected observational data of 
623 253 primary total hip replacements performed in 
England and Wales.
Methods
Study design and participants 
In this observational cohort study, we report analyses of 
data for England and Wales from the National Joint 
Registry (NJR) for England, Wales, Northern Ireland, and 
the Isle of Man between April 1, 2003, and Dec 31, 2014. 
NJR data were linked to Hospital Episode Statistics and 
Patient Episode Database for Wales to obtain data on 
inpatient and day case admissions. Data from the Office for 
National Statistics were linked to obtain the date of death.
We included all patients who had a primary hip 
replacement between April 1, 2003, and Dec 31, 2013, in 
the study. Patient consent was obtained for data collection 
and linkage by the NJR. According to the National Health 
Service Health Research Authority, separate consent and 
ethical approval were not required for this study.
Procedures
We analysed primary hip replacements performed 
between April 1, 2003, and Dec 31, 2013, and revision 
procedures due to PJI that occurred after the primary 
replacement between April 1, 2003, and Dec 31, 2014. The 
reason for revision was recorded by clinicians at the time 
of the revision procedure and reflected a clinical 
judgment sufficient to lead the surgeon to perform an 
invasive procedure tailored to tackle a PJI. The diagnosis 
and treatment strategy for PJI was at the discretion of 
the surgeon and treating unit and was reflective of 
contemporary practice over the study period, with raised 
inflammatory markers, joint specific symptoms, sinuses, 
and positive microbiological cultures13 being common 
diagnostic features over that period.
Each patient who had a primary hip replacement was 
followed up for a minimum of 12 months until the end of 
the observation period (Dec 31, 2014) or until the date of 
revision for PJI, revision for another indication, or death. 
Revisions for PJI included debridement and implant 
retention with modular exchange, a single or a two-stage 
revision procedure.14
We considered the patient characteristics age, sex, 
ethnicity, BMI, American Society of Anaesthesiologists 
(ASA) grade, and comorbidities. We obtained data for 
ethnicity and comorbidities from the Hospital Episode 
Statistics records. We used ICD-10 codes to classify 
comorbidities for which patients had been admitted to 
hospital in the 5 years preceding their primary operation 
(appendix).15
We considered surgical factors such as indication for 
surgery, anaesthesia type, thromboprophylaxis regime, 
surgical approach, hip replacement type, bearing surface, 
use of bone graft, and occurrence of intraoperative 
complications.
We considered health system factors such as hospital 
type, funding stream, country, operating surgeon grade, 
consultant involvement, and volume of hip surgeries 
(categorised into quartiles) performed by the hospital, 
operating surgeon and surgeon in charge of the 
procedure in the preceding 12 months.
Statistical methods
We first investigated the associations between the risk 
factors and risk of revision for PJI across the overall follow-up 
period. We used Poisson multilevel models accounting for 
clustering at unit level (random intercept). Clustering at 
surgeon level was negligible and therefore ignored.
PJI management varies according to the time since the 
primary procedure and onset of infection. Early onset of 
PJI within 24 months of primary procedure is generally 
considered to result from the primary intervention. 
Later onset of PJI is more likely to be due to 
haematogenous spread. For patients with early post- 
operative or acute haematogenous PJI and a short duration 
of symptoms, debridement, modular exchange, and 
implant retention rather than full revision are appropriate.6 
Therefore, we reinvestigated the associations over several 
at- risk postoperative periods: 0–3 months, 3–6 months, 
6–12 months, 12–24 months, and more than 24 months. 
We split each patient’s at-risk period (time elapsed between 
their primary procedure and endpoint) according to the 
time spent in each of these periods and we assigned the 
revision for PJI status (revised for PJI or not) to the relevant 
period. We used a piece-wise exponential multilevel model 
with period-specific effects to assess these associations—ie, 
their rate ratios (RR) and 95% CIs across these time-
periods.16,17 We did analyses by running MLwiN from Stata 
14.1 (StataCorp LP, TX, USA) using Markov Chain Monte 
Carlo methods.18 To account for test multiplicity, we derived 
adjusted p values using Simes’ false discovery rate testing 
controlling procedure.19,20 To be confident that 95% of the 
effects tested were not due to chance, we only discussed 
evidence of association for adjusted p value of 0·05 or 
lower.
We did the analyses on the overall sample for all 
exposures except for ethnicity and comorbidities, which 
we investigated in the 495 456 patients operated on in 
England with a record of hospital admission in HES but 
not in PEDW, and no evidence of residency outside 
England (appendix). We adjusted the regressions for age, 
sex, ASA grade, and BMI. BMI is an important risk factor 
for PJI but has substantial missing data in the NJR (47%), 
partly because it was not included as a variable in 
the early data collection forms. We used a multiple 
imputation strategy to impute BMI, assuming that data 
were missing at random, using a Gaussian normal 
regression imputation model with the factors age, sex, 
and ASA used as covariates, and the log of the observed 
event or censoring time and revision for PJI status. Due 
to the computational time required by each multilevel 
piece-wise model, we computed only five imputations 
See Online for appendix
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and combined regression estimates by Rubin’s rules. 
Unadjusted and adjusted models without BMI are 
available on request. To avoid overadjustment, we did not 
adjust models investigating the effect of comorbidities 
for ASA grade, a proxy indicator of comorbid profile.
Role of the funding source
The National Institute for Health Research had no role in 
study design, data collection analysis, interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
Results
623 253 primary hip procedures were done in 
460 different surgical units with a median (IQR) of 
1050 (460–1940) per unit. Baseline study sample 
characteristics are presented in figure 1 and the table. 
2705 primary procedures were subsequently revised for 
an indication of PJI after a median (IQR) follow-up of 
4·6 years (2·6–7·0); 14% (n=372) of these within 
3 months, 8% (n=204) in 3–6 months, 14% (n=374) in 
6–12 months, 23% (n=612) in 12–24 months, and 
42% (n=1143) beyond 24 months from the primary 
procedure. The mean patient age was 68 years (SD 11). 
The sample is presented by time periods in the appendix. 
In 523 (27%) of the 1959 two-stage revision procedures 
performed for PJI, only a second stage procedure was 
recorded in the NJR. Patients with incompletely 
registered two-stage procedures did not differ from those 
with complete procedures and their time to first-stage 
procedure was estimated (appendix).
RR of PJI revision surgery are presented in appendix.
Men were at higher risk of revision for PJI in all time 
periods than women (figure 2). Over the entire follow-up, 
the risk was lower for patients older than 70 years than 
for patients younger than 60 years. However, this reduced 
risk was only observed after the first 6 months (appendix). 
BMI of 30 kg/m² or higher was associated with an 
increased risk compared with BMI of less than 25 kg/m². 
Patients with an ASA grade of 2 or higher were at greater 
risk than healthy patients (table). This was particularly 
evident during the first 6 months (appendix).
Patients with a pre-existing history of chronic pulmonary 
disease, diabetes, liver disease, congestive heart failure, or 
connective tissue and rheumatologic diseases had a 
higher risk than did those without pre-existing history of 
these diseases (figure 2). Patients with diabetes or 
dementia were at increased risk of early revision for PJI 
(figure 3). Patients with liver disease were only at high risk 
beyond 24 months. No time-specific effect was observed 
for other comorbidities (appendix).
The risk varied according to the indication for the 
primary procedure. Patients operated on for osteoarthritis 
were less likely to be revised for PJI than those without 
osteoarthritis. Patients operated on for a fractured neck 
of femur, avascular necrosis (figure 2), or history of 
previous infection of the operated joint were at increased 
risk (table; appendix). A fractured neck of the femur was 
only associated with an increased risk of early revision 
for PJI (figure 3).
Operations done via a posterior surgical approach had 
the lowest risk of revision for PJI compared with other 
surgical approaches (figure 2). The surgical approach 
did not influence the early risk of revision for PJI 
(figure 3), but from 3 months onwards patients who had 
undergone a lateral approach were at higher risk 
(appendix).
Patients who had a primary hip resurfacing were at 
lower risk of revision for PJI (figure 2), but this lower risk 
was not evident in the first 3 postoperative months 
(figure 3). In the early postoperative period, patients who 
Figure 1: Description of the sample
HES=Hospital Episode Statistics for England. PEDW=Patient Episode Database for Wales. *Only data for England and Wales were considered; data collection for Northern Ireland started Feb 2, 2013, and 
primary revision procedures could not be considered due to their limited number and restricted follow-up. Data collection for the Isle of Man started on July 1, 2015, after the endpoint of this study and 
were not considered. †As recorded in HES for the 5 years preceding the primary hip replacement.
2705 revised for a prosthetic
joint infection
(6133 person-years)
16 785 revised for another  
indication 
(54 355 person-years)
495 456 surgeries done in England 
linked with HES (sample 
used to analyse  
comorbidities and
ethnicity)
68 450 deceased
(277 990 person-years)
535 313 followed-up until 
endpoint (Dec 31, 2014; 
2 748 404 person-years)
127 797 excluded from analyses including comorbidities and ethnicity
86 503 surgeries done in England not linked with HES or PEDW 
35 854 surgeries done in England or Wales linked with PEDW
5017 surgeries done in Wales not linked with PEDW
423 with evidence of residency outside of England†
623 253 primary hip replacements performed in England and Wales from
the National Joint Registry* (sample used to analyse all
factors except comorbidities and ethnicity)
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Patients, n Person-
years
Cases, n Incidence per 
1000 person-
years (95% CI)
Sex
Female 372 256 1 849 691 1243 0·67 (0·64–0·71)
Male 250 997 1 237 170 1462 1·18 (1·12–1·24)
Age, years
<60 131 803 688 000 739 1·07 (1·00–1·15)
60–69 191 128 977 963 942 0·96 (0·90–1·03)
70–79 210 387 1 033 850 782 0·76 (0·70–0·81)
≥80 89 935 387 049 242 0·63 (0·55–0·71)
Ethnicity
White 469 129 2 256 675 2308 1·02 (0·98–1·07)
Black African 
origin
2855 13 152 12 0·91 (0·47–1·59)
South Asian 1605 7223 6 0·83 (0·30–1·81)
Other and 
mixed
3235 14 405 14 0·97 (0·53–1·63)
Unclear 18 632 96 433 25 0·26 (0·17–0·38)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
Body-mass index, kg/m²
<25 71 584 297 686 272 0·91 (0·81–1·03)
25–29·9 133 037 557 826 580 1·04 (0·96–1·13)
≥30 125 856 517 278 941 1·82 (1·70–1·94)
Missing 292 776 1 714 072 912 0·53 (0·50–0·57)
American Society of Anaesthesiologists grade
1 114 367 657 059 482 0·73 (0·67–0·80)
2 418 335 2 036 022 1772 0·87 (0·83–0·91)
3–5 90 551 393 780 451 1·15 (1·04–1·26)
Chronic pulmonary disease
No 433 003 2 127 270 2064 0·97 (0·93–1·01)
Yes 62 453 260 618 301 1·15 (1·03–1·29)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
Diabetes
No 453 057 2 209 507 2120 0·96 (0·92–1·00)
Yes 42 399 178 381 245 1·37 (1·21–1·56)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
Dementia
No 493 382 2 381 198 2355 0·99 (0·95–1·03)
Yes 2074 6690 10 1·49 (0·72–2·75)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
Liver disease
No 491 430 2 372 883 2327 0·98 (0·94–1·02)
Yes 4026 15 005 38 2·53 (1·79–3·48)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
Congestive heart failure
No 484 748 2 346 960 2307 0·98 (0·94–1·02)
Yes 10 708 40 928 58 1·42 (1·08–1·83)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
Connective tissue and rheumatic disease 
No 473 594 2 292 733 2251 0·98 (0·94–1·02)
Yes 21 862 95 156 114 1·20 (0·99–1·44)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
(Table continues in next column)
Patients, n Person-
years
Cases, n Incidence per 
1000 person-
years (95% CI)
(Continued from previous column)
Cancer
No 473 046 2 299 171 2262 0·98 (0·94–1·03)
Non-
metastatic 
cancer
18 511 77 688 85 1·09 (0·87–1·35)
Metastatic 
cancer
3899 11 030 18 1·63 (0·97–2·58)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
Cerebrovascular disease
No 485 508 2 348 220 2329 0·99 (0·95–1·03)
Yes 9948 39 668 36 0·91 (0·64–1·26)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
Myocardial infarction
No 481 922 2 330 894 2305 0·99 (0·95–1·03)
Yes 13 534 56 995 60 1·05 (0·80–1·36)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
Paraplegia and hemiplegia
No 493 415 2 379 416 2351 0·99 (0·95–1·03)
Yes 2041 8472 14 1·65 (0·90–2·77)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
Peptic ulcer disease
No 488 994 2 358 642 2333 0·99 (0·95–1·03)
Yes 6462 29 247 32 1·09 (0·75–1·54)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
Peripheral vascular disease
No 485 720 2 349 624 2318 0·99 (0·95–1·03)
Yes 9736 38 265 47 1·23 (0·90–1·63)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
Renal disease
No 479 616 2 337 545 2311 0·99 (0·95–1·03)
Yes 15 840 50 343 54 1·07 (0·81–1·40)
Unavailable* 127 797 698 972 340 0·49 (0·44–0·54)
Osteoarthritis
No 43 673 189 279 249 1·32 (1·16–1·49)
Yes 579 580 2 897 582 2456 0·85 (0·81–0·88)
Fractured neck of femur
No 610 693 3 043 483 2639 0·87 (0·83–0·90)
Yes 12 560 43 378 66 1·52 (1·18–1·94)
Previous hip infection
No 622 597 3 083 806 2683 0·87 (0·84–0·90)
Yes 656 3055 22 7·20 (4·51–10·90)
Avascular necrosis
No 607 308 3 007 214 2597 0·86 (0·83–0·90)
Yes 15 945 79 647 108 1·36 (1·11–1·64)
Dysplasia or congenital dislocation
No 613 710 3 038 036 2677 0·88 (0·85–0·92)
Yes 9543 48 825 28 0·57 (0·38–0·83)
(Table continues in next column)
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had undergone an uncemented, hybrid, or reverse hybrid 
total hip replacement (THR other, figure 3B) were at 
higher risk than those with cemented implants but from 
3 to 24 months, they were at lower or similar risk 
(appendix). Further analysis showed a higher early risk of 
revision in patients with hybrid implant THRs (RR<3mth 1·7, 
95% CI 1·2–2·3) than in those with reverse hybrid 
implants (0·9, 0·4–2·0).
Patients, n Person-
years
Cases, n Incidence per 
1000 person-
years (95% CI)
(Continued from previous column)
Inflammatory arthropathy
No 614 117 3 040 372 2665 0·88 (0·84–0·91)
Yes 9136 46 489 40 0·86 (0·61–1·17)
Surgical approach
Posterior 337 188 1 565 913 1242 0·79 (0·75–0·84)
Lateral 257 487 1 399 287 1334 0·95 (0·90–1·01)
Other 28 578 121 661 129 1·06 (0·89–1·26)
Procedure
Resurfacing 36 503 245 085 174 0·71 (0·61–0·82)
Total hip 
replacement 
cemented
229 008 1 196 702 1014 0·85 (0·80–0·90)
Total hip 
replacement 
uncemented
241 278 1 104 196 1074 0·97 (0·92–1·03)
Total hip 
replacement 
other
116 464 540 878 443 0·82 (0·74–0·90)
Type of bearing
Metal-on-
polyethylene
367 226 1 805 843 1505 0·83 (0·79–0·88)
Metal-on-
metal
68 761 447 609 526 1·18 (1·08–1·28)
Ceramic-on-
polyethylene
73 607 328 183 252 0·77 (0·68–0·87)
Ceramic-on-
ceramic 
99 651 428 600 342 0·80 (0·72–0·89)
Ceramic-on-
metal or 
metal-on-
ceramic 
2263 10 553 20 1·90 (1·16–2·93)
Other 11 745 66 073 60 0·91 (0·69–1·17)
General anaesthesia
No 323 710 1 532 200 1317 0·86 (0·81–0·91)
Yes 299 543 1 554 661 1388 0·89 (0·85–0·94)
Nerve block anaesthesia
No 558 990 2 751 591 2426 0·88 (0·85–0·92)
Yes 64 263 335 270 279 0·83 (0·74–0·94)
Epidural anaesthesia
No 568 425 2 752 938 2415 0·88 (0·84–0·91)
Yes 54 828 333 923 290 0·87 (0·77–0·97)
Spinal anaesthesia used
No 244 716 1 302 912 1180 0·91 (0·85–0·96)
Yes 378 537 1 783 949 1525 0·85 (0·81–0·90)
Thromboprophylaxis regimen 
Chemical 562 884 2 691 005 2363 0·88 (0·84–0·91)
Non-
chemical 
60 369 395 856 342 0·86 (0·77–0·96)
Acetabulum bonegraft
No 597 493 2 958 905 2588 0·87 (0·84–0·91)
Yes 25 760 127 956 117 0·91 (0·76–1·10)
(Table continues in next column)
Patients, n Person-
years
Cases, n Incidence per 
1000 person-
years (95% CI)
(Continued from previous column)
Femur bonegraft
No 618 407 3 062 174 2667 0·87 (0·84–0·90)
Yes 4846 24 687 38 1·54 (1·09–2·11)
Intraoperative event
No 615 874 3 053 562 2663 0·87 (0·84–0·91)
Yes 7379 33 299 42 1·26 (0·91–1·70)
Place of surgery
England 588 086 2 914 439 2539 0·87 (0·84–0·91)
Wales 35 167 172 422 166 0·96 (0·82–1·12)
Funding
NHS 506 727 2 393 636 2172 0·91 (0·87–0·95)
Independent 90 650 500 738 354 0·71 (0·64–0·78)
Unspecified 25 876 192 487 179 0·93 (0·80–1·08)
Grade of operating surgeon
Consultant 526 789 2 599 225 2253 0·87 (0·83–0·90)
Other 48 598 253 948 215 0·85 (0·74–0·97)
Consultant involvement
Operating 526 789 2 599 225 2253 0·87 (0·83–0·90)
Assisting 33 262 158 323 163 1·03 (0·88–1·20)
Not involved 63 202 329 312 289 0·88 (0·78–0·98)
Total volume (operating surgeon) of hip replacements performed in 
previous 12 months
≤28 164 527 928 504 836 0·90 (0·84–0·96)
29–63 158 385 797 348 752 0·94 (0·88–1·01)
64–148 153 734 718 359 583 0·81 (0·75–0·88)
>148 146 607 642 649 534 0·83 (0·76–0·90)
Total volume (surgeon in charge) of hip replacements performed in 
previous 12 months
≤41 165 921 949 331 828 0·87 (0·81–0·93)
42–84 158 134 780 769 682 0·87 (0·81–0·94)
85–148 152 186 717 523 611 0·85 (0·79–0·92)
>148 147 012 639 238 584 0·91 (0·84–0·99)
Total volume (hospital) of hip replacements performed in previous 12 
months
≤143 160 375 960 028 789 0·82 (0·77–0·88)
144–256 158 020 799 114 659 0·82 (0·76–0·89)
257–406 154 586 671 995 581 0·86 (0·80–0·94)
>406 150 272 655 724 676 1·03 (0·95–1·11)
*Information on ethnicity and comorbidities are only available on the 
495 456 patients operated in England with a Hospital Episode Statistics record—
with no record in Patient Episode Database for Wales and no evidence of 
residency outside England (see figure 1 and appendix for more details). 
Table: Sample description and incidence rates
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The risk of revision for PJI was also influenced by the 
type of bearing surfaces and this varied according to 
the time period. In the early postoperative period, no 
differences were observed (figure 3). Between 3 and 
24 months, metal-on-metal THRs had a lower or 
similar risk than did metal-on-polyethylene THRs; 
beyond 24 months, the risk was higher for 
metal-on-metal (appendix). When the model was 
further adjusted for the type of surgery (resurfacing 
and THR cemented or not) the higher revision risk 
for PJI in the metal-on-metal group was identified 
earlier, from 12 months postoperation onwards 
(RR12–24mth 1·8, 95% CI 1·3–2·3; RR>24mth 2·2, 1·8–2·6). 
Ceramic-on-ceramic and ceramic-on-poly- ethylene 
surfaces were associated with a lower risk of long-term 
revision (from 12 months for ceramic-on-ceramic and 
24 months for ceramic-on-polyethylene postoperation 
onwards) than metal-on-polyethylene bearings, which 
Figure 2: Risk factors of revision for prosthetic joint infection for the overall postoperative period, 2003–13
Reference category in parentheses. BMI=body-mass index. ASA=American Society of Anaesthesiologists. THR=total hip replacement. MoM=metal-on-metal. 
MoP=metal-on-polyethylene. CoP=ceramic-on-polyethylene. CoC=ceramic-on-ceramic. CoM=metal-on-ceramic. *Adjusted p value <0·05 (details in the appendix 
alongside the rate ratios and 95% CIs). 
A Patient factors
Sex male* (female)
Age 60–69 years (<60)
Age 70–79 years* (<60)
Age ≥80* (<60)
BMI 25–29·9* (<25)
BMI ≥30* (<25)
ASA 2* (1)
ASA 3–5* (1)
Chronic pulmonary disease*
Diabetes*
Dementia
Liver disease*
Congestive heart failure*
Connective tissue-rheumatic disease*
Cancer non-metastatic
Cancer metastatic 
Cerebrovascular disease
Myocardial infarction
Paraplegia or hemiplegia
Peptic ulcer disease
Peripheral vascular disease
Renal disease
C Health system factors
Place of surgery Wales (England)
Independent funding (NHS)
Unknown funding (NHS)
Grade operating surgeon other (consultant)
Assisting consultant (operating consultant)
No consultant (operating consultant)
Operating surgeon volume 28–63 (≤28)
Operating surgeon volume 63–114* (≤28)
Operating surgeon volume >114 (≤28)
In charge surgeon volume 42–84 (≤41)
In charge surgeon volume 84–148 (≤41)
In charge surgeon volume >148 (≤41)
Hospital surgeon volume 143–256 (≤143)
Hospital surgeon volume 256–406 (≤143)
Hospital surgeon volume >406* (≤143)
B Surgery factors
Osteoarthritis*
Fractured neck of femur*
Avascular necrosis*
Dysplacia or congenital dislocation
Inflammatory arthropathy
Lateral surgical approach* (posterior)
Other surgical approach* (posterior)
Resurfacing* (THR cemented)
THR uncemented (THR cemented)
THR other (THR cemented)
Bearing MoM (MoP)
Bearing CoP* (MoP)
Bearing CoC* (MoP)
Bearing CoM* (MoP)
Bearing undetermined (MoP)
General anaesthesia
Nerve block anaesthesia
Epidural anaesthesia
Spinal anaesthesia
Non-chemical thromboprophyl axis (chemical)
Acetabulum bone graft
Femur bone graft*
Intraoperative event
1·00 2·01·50·5 2·5 3·0 3·5
1·00 2·01·50·5 2·5 3·0 3·5
1·00 2·01·50·5 2·5 3·0 3·5
Rate ratio
Rate ratio
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also had a higher risk of long-term revision for PJI 
(appendix).
Little or no difference in the risk of revision for PJI was found 
for the choice of anaesthetic technique, thromboprophylaxis 
regime, use of acetabular bone graft, or experience of 
intraoperative complication (figures 2, 3; appendix) Patients 
who received a femoral bone graft during the primary 
procedure were at higher risk of PJI with no evidence of a 
postoperative period-specific effect (figure 3; appendix).
The risk of revision for PJI was not different between 
Wales and England nor between the funding sources of 
the primary procedure (figure 2).
Revision for PJI was not influenced by the grade of the 
operating surgeon and the presence or absence of a 
consultant surgeon during surgery (figure 2).
Operating surgeons who had performed over 
63 procedures in the 12 months preceding the primary 
surgery were weakly associated with a lower risk of 
Figure 3: Risk factors of revision for prosthetic joint infection for the first 3 postoperative months
Reference category in parentheses. BMI=body-mass index. ASA=American Society of Anaesthesiologists. THR=total hip replacement. MoM=metal-on-metal. 
MoP=metal-on-polyethylene. CoP=ceramic-on-polyethylene. CoC=ceramic-on-ceramic. CoM=metal-on-ceramic. *Adjusted p value <0·05 (details in the appendix 
alongside the rate ratios and 95% CIs). 
A Patient factors
Sex male* (female)
Age 60–69 years (<60)
Age 70–79 years* (<60)
Age ≥80 (<60)
BMI 25–29·9* (<25)
BMI ≥30* (<25)
ASA P2* (P1)
ASA P3–P5* (P1)
Chronic pulmonary disease
Diabetes*
Dementia*
Liver disease
Congestive heart failure
Connective tissue-rheumatic disease
Cancer non-metastatic
Cancer metastatic 
Cerebrovascular disease
Myocardial infarction
Paraplegia or hemiplegia
Peptic ulcer disease
Peripheral vascular disease
Renal disease
C Health system factors
Place of surgery Wales (England)
Independent funding (NHS)
Unknown funding (NHS)
Grade operating surgeon other (consultant)
Assisting consultant (operating consultant)
No consultant (operating consultant)
Operating surgeon volume 28–63 (≤28)
Operating surgeon volume 63–114* (≤28)
Operating surgeon volume >114 (≤28)
In charge surgeon volume 42–84 (≤41)
In charge surgeon volume 84–148 (≤41)
In charge surgeon volume >148 (≤=41)
Hospital surgeon volume 143–256 (≤143)
Hospital surgeon volume 256–406 (≤143)
Hospital surgeon volume >406* (≤143)
B Surgery factors
Osteoarthritis
Fractured neck femur*
Avascular necrosis
Dysplacia or congenital dislocation
Inflammatory arthropathy
Lateral surgical approach (posterior)
Other surgical approach (posterior)
Resurfacing (THR cemented)
THR uncemented* (THR cemented)
THR other* (THR cemented)
Bearing MoM (MoP)
Bearing CoP* (MoP)
Bearing CoC* (MoP)
Bearing CoM* (MoP)
Bearing undetermined (MoP)
General anaesthesia
Nerve block anaesthesia
Epidural anaesthesia
Spinal anaesthesia
Non-chemical thromboprophyl axis (chemical)
Acetabulum bone graft
Femur bone graft
Intraoperative event
20 431 5 6 7 8 20 431 5 6 7 8
20 431 5 6 7 8
Rate ratio
Rate ratio
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revision for PJI than surgeons with a lower volume 
(figure 2). This pattern was inconsistent between 
time-periods and did not influence the early risk of 
revision for PJI (figure 3; appendix). The volume of all 
hip procedures done by the surgeon in charge of the 
surgery did not affect the risk of revision (figure 2). The 
risk of revision for PJI was higher in the first 3 months 
after primary surgery in hospitals that had performed 
over 255 hip procedures in the 12 months preceding the 
primary surgery than with hospitals with a small volume 
of activity (figure 3). No specific difference in the rate 
ratios were found  beyond this period or for units with 
lower volumes of hip procedures (appendix).
Discussion
At the patient level, men, younger patients, and those 
with high BMI or high ASA grades had an increased risk 
of revision for PJI. Comorbidities that increased the risk 
of revision for PJI included chronic pulmonary disease, 
diabetes, dementia, liver disease, congestive heart failure, 
and connective tissue or rheumatic diseases. These 
comorbidities and elevated BMI can potentially be 
optimised before surgery. A targeted preoperative 
intervention for male patients with high BMI and specific 
comorbidities seems particularly relevant.
At the surgical level, patients undergoing THR for 
fractured neck of femur or avascular necrosis were at 
higher risk of revision for PJI. Patients with a fracture are 
different to those who have conditions such as 
osteoarthritis, generally being older with a higher risk of 
mortality.21 Conditions that cause avascular necrosis, such 
as steroid use or irradiation, cause immunosuppression 
and also predispose towards PJI. The markedly higher 
risk in those with historical infection of the hip is novel, 
though unsurprising, and might be due to quiescent 
bacteria or other immune conditions that predispose to 
PJI. Lateral surgical approach and use of femoral bone 
graft also increased the risk. The increased risk with the 
lateral surgical approach is a novel finding that we 
postulate is due to increased tissue damage and bleeding 
caused by violating the abductor mechanism. Previous 
studies have suggested that the lateral approach is 
associated with more bleeding,22 worse patient related 
outcomes,23 and higher mortality.24 Approximately one 
third of hip replacements undertaken in England and 
Wales in 2016, still utilised this approach—although its 
use is declining.21 Early revision for PJI was higher in 
those receiving uncemented than cemented implants 
independent of bearing surface. At later time points, the 
risk was lower for uncemented THRs and resurfacings. 
This might reflect an initial protective effect of antibiotic 
impregnated bone cement. Long-term risk was higher in 
metal-on-metal bearings, possibly due to the soft tissue 
destruction associated with these implants,25 and was 
lower in bearings that included ceramic heads, which is 
concordant with a report26 from the Medicare population 
in the USA. In this Medicare population, ceramic 
bearings were used in younger and healthier patients. 
Our study adjusted for age and health status, which 
should mitigate the effects of any selection bias. A 
meta-analysis27 also showed weak evidence of reduced 
risk of PJI for ceramic bearing surfaces.
Factors at the health-care system level appear to be less 
important with no marked sustained associations across 
the time periods studied.
Consistent with previous studies,10,12,28 we observed 
higher risk in men and patients with high BMI. Contrary 
to previous findings,10,12 younger patients were at higher 
risk, which could reflect the increased follow up in our 
study. Older patients could be at lower risk due to a 
propensity to non-operative management of PJI in this 
group. Smoking has previously been identified as a risk 
factor,10,29 and although we did not have information on 
smoking habit, the surrogate comorbidity of chronic 
pulmonary disease was associated with increased risk. 
Evidence of an association between alcohol intake and 
increased risk has been inconsistent.30,31 We observed 
higher risk in patients with liver disease, but this might 
represent several pathologies. Our study corroborates the 
previous findings10,30,32 of increased risk in patients with 
diabetes, rheumatoid arthritis, and congestive heart 
failure. We have shown for the first time that dementia is 
associated with an increased risk of early revision for 
PJI, which might reflect the high prevalence of other 
comorbidities in these patients.
The current study has several strengths. To our 
knowledge, this is the largest and most comprehensive 
investigation of several patient, surgical, and health-care 
related factors and their risk for revision for PJI of the 
hip. We used a large-scale cohort design comprising 
more participants (n=623 253) than those of the most 
up-to-date review on the topic (n=512 508 hip and knee 
replacements).10 Other strengths include the 
longer term follow-up of the cohort (median 4·6 years) 
and cutting-edge statistical analyses, which include the 
assessment of the effects of these potential risk factors 
at time-specific periods. 
Our study has some limitations. Although pros- 
pectively collected, our data is observational and we can 
only draw inferences on the nature and magnitude of the 
associations but cannot establish causation. In the UK, 
no national gold standards have been agreed upon that 
are available to orthopaedic surgeons to diagnose PJI. As 
such, the reported indication of PJI in the NJR might 
vary between units but is reflective of contemporary 
practice with raised inflammatory markers, joint specific 
symptoms, sinuses, and positive microbiological cultures 
being used to diagnose PJI.13 The PJI diagnosis reflects a 
clinical judgment sufficient to lead the surgeon to 
conduct a very severe and invasive procedure tailored to 
tackle a PJI. Issues relating to under-reporting of revision 
for PJI, and thus potentially lower incidence estimates, 
are acknowledged.33 Linkage of the NJR data to 
microbiology data could reduce any misdiagnoses of PJI 
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but has proven to be of limited generalisability with 12% 
NJR linkage achievable.34 
The associations we have identified might vary with 
different causative pathogens, but unfortunately we do 
not have the data to explore this. Our findings should 
be considered as conservative estimates of the risk 
factors with the strongest effects. The investigations of 
the effect of comorbidities were limited to a subset of 
NJR patients linked to HES. This subset had higher 
ASA grades and therefore higher rate of revision for PJI 
than those excluded from these investigations, but they 
did not differ in terms of age, sex, BMI, or surgical 
characteristics, suggesting little evidence of differential 
selection bias. All other factors were investigated on the 
entire sample.
We have done appropriate modelling to adjust for 
known relevant confounders but residual confounding is 
still possible. We had no specific data on confounders, 
such as smoking and alcohol consumption, but have 
surrogate markers, such as chronic pulmonary disease 
and liver disease. BMI was not collected in the early years 
of the registry necessitating imputation of the data as with 
a previous study on this dataset.24 Competing risk due to 
revision for another cause or death, which in combination 
affected 55% of the primary hip replacements in the 
dataset during the period of observation, could not be 
accounted for in the modelling strategy. This was a 
pragmatic decision because we chose a strategy focusing 
on time-specific effects while accounting for the clustering 
nature of the data to disentangle the effect associated with 
surgical factors (likely to be more marked in the short-term 
to mid-term follow-up period) from those associated with 
health-risk behaviour (likely to be more marked in the 
mid-term to long-term follow-up period). This strategy 
was optimal because evidence supports non-proportional 
hazard rates. Finally, it was not possible to investigate any 
ethnic disparities in terms of revision for PJI due to the 
insufficient number of ethnic minority patients revised 
for PJI.
Preventive strategies for PJI largely focus on hygiene, 
use of protective equipment, management of care 
equipment and occupational exposure, and safe care of 
linen, the environment, and waste.35 Combinations of 
systemic antibiotics, antibiotic-impregnated cement, and 
conventional operating theatre ventilation are considered 
cost effective for preventing PJI.35 Identification of patient 
factors associated with increased need for revision for PJI 
can further guide the development of interventions and 
help target the provision of appropriate preventative care. 
Using the largest longitudinal sample of primary hip 
replacements, we have shown several modifiable and 
non-modifiable factors to be associated with the risk of 
revision for a PJI after a primary hip replacement. For 
patients about to have hip replacement, identification of 
modifiable factors, use of targeted interventions, and 
beneficial modulation of some of these factors could be 
effective in reducing the incidence of PJI. It is important 
for clinicians to consider the non-modifiable factors, and 
the factors that exhibit time-specific effects on the risk of 
PJI, to counsel patients appropriately preoperatively.
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